Krishnamurti Lakshmanan
Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Emory University, Atlanta, GA, United States.
Front Pediatr. 2021 Jan 5;8:551170. doi: 10.3389/fped.2020.551170. eCollection 2020.
Sickle cell disease (SCD) is a severe autosomal recessively inherited disorder of the red blood cell characterized by erythrocyte deformation caused by the polymerization of the abnormal hemoglobin, which leads to erythrocyte deformation and triggers downstream pathological changes. These include abnormal rheology, vaso-occlusion, ischemic tissue damage, and hemolysis-associated endothelial dysfunction. These acute and chronic physiologic disturbances contribute to morbidity, organ dysfunction, and diminished survival. Hematopoietic cell transplantation (HCT) from HLA-matched or unrelated donors or haploidentical related donors or genetically modified autologous hematopoietic progenitor cells is performed with the intent of cure or long-term amelioration of disease manifestations. Excellent outcomes have been observed following HLA-identical matched related donor HCT. The majority of SCD patients do not have an available HLA-identical sibling donor. Increasingly, however, they have the option of undergoing HCT from unrelated HLA matched or related haploidentical donors. The preliminary results of transplantation of autologous hematopoietic progenitor cells genetically modified by adding a non-sickling gene or by genomic editing to increase expression of fetal hemoglobin are encouraging. These approaches are being evaluated in early-phase clinical trials. In performing HCT in patients with SCD, careful consideration must be given to patient and donor selection, conditioning and graft-vs.-host disease regimen, and pre-HCT evaluation and management during and after HCT. Sociodemographic factors may also impact awareness of and access to HCT. Further, there is a substantial decisional dilemma in HCT with complex tradeoffs between the possibility of amelioration of disease manifestations and early or late complications of HCT. The performance of HCT for SCD requires careful multidisciplinary collaboration and shared decision making between the physician and informed patients and caregivers.
镰状细胞病(SCD)是一种严重的常染色体隐性遗传性红细胞疾病,其特征是异常血红蛋白聚合导致红细胞变形,进而引起红细胞变形并引发下游病理变化。这些病理变化包括异常流变学、血管闭塞、缺血性组织损伤以及与溶血相关的内皮功能障碍。这些急慢性生理紊乱会导致发病、器官功能障碍和生存期缩短。进行来自人类白细胞抗原(HLA)匹配或不相关供体、单倍体相合相关供体或基因修饰自体造血祖细胞的造血细胞移植(HCT),目的是治愈或长期改善疾病表现。在HLA完全相同的匹配相关供体进行HCT后已观察到良好的结果。大多数SCD患者没有可用的HLA完全相同的同胞供体。然而,越来越多的患者可以选择接受来自不相关HLA匹配或相关单倍体相合供体的HCT。通过添加非镰状基因或进行基因组编辑以增加胎儿血红蛋白表达来对自体造血祖细胞进行基因修饰后进行移植的初步结果令人鼓舞。这些方法正在早期临床试验中进行评估。在对SCD患者进行HCT时,必须仔细考虑患者和供体的选择、预处理和移植物抗宿主病方案,以及HCT期间和之后的HCT前评估和管理。社会人口统计学因素也可能影响对HCT的认知和获得HCT的机会。此外,在HCT中存在重大的决策困境,在改善疾病表现的可能性与HCT的早期或晚期并发症之间存在复杂的权衡。对SCD进行HCT需要医生与明智的患者及护理人员之间进行仔细的多学科协作和共同决策。